KB707
AXP000196.1 · Viral vector gene therapy
- Platform
- HSV-1 (replication-defective)
- Originator
- Krystal Biotech
- Sponsor
- Krystal Biotech
Names
| Name | Type | Source |
|---|---|---|
| KB707 | preferred name, code | curator, press |
| KYANITE-1 ambiguous | synonym | press |
| OPAL-1 ambiguous | synonym | press |
Virus
- Role
- In vivo gene transfer
- Family
- Herpesviridae
- Virus
- herpes simplex virus 1 (NCBI Taxonomy 10298)
- Replication
- non replicating
- Modifications
- replication-incompetent HSV-1 backbone; human IL-12 and IL-2 cassettes
- Transgenes
- IL12A, IL12B, IL2
- Route
- intratumoral, inhaled
- Source
- evidence
Approvals
No regulatory approval recorded.
Clinical trials (2)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT06228326 | A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs | Recruiting | Phase 1/2 | 2024-04-17 | 2027-02 | 250 | Advanced Cancer; Lung Cancer (NSCLC); Lung Cancer Metastatic; Lung Cancer, Non-small Cell; Solid Tumor, Adult |
| NCT05970497 | A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors | Recruiting | Phase 1/2 | 2023-10-31 | 2027-07 | 240 | Cancer; Cutaneous Melanoma; Melanoma Stage III; Melanoma Stage IV |
Recent changes
No changes recorded in its trials yet.
Notes
Replication-incompetent HSV-1 vector delivering human IL-12 and IL-2 to tumours; given intratumorally (phase 1 OPAL-1, NCT05970497) and by inhalation for lung tumours and pulmonary metastases (phase 1 KYANITE-1, NCT06228326). FDA fast track for both routes. Recorded as in_vivo_gene_transfer, not oncolytic: the vector does not replicate.
How to cite
KB707 (AXP000196.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000196.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.